Metrics as of 10/14/2026, 08:25 PM (Berlin time), refresh in progress.
Innoviva Stock
Innoviva, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Pavel Raifeld
- Employees
- 159
- Market cap
- $1.6 B
- IPO
- 05/10/2004
- Web
- www.inva.com
Innoviva, Inc. is a healthcare company within the biotechnology industry headquartered in Burlingame, US. The company focuses on the worldwide development and marketing of medical treatments. Its current product lineup prominently includes several once-daily combination therapies, such as RELVAR/BREO ELLIPTA, which…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Innoviva stock: price history
1D
+1.7%
1W
+0.2%
1M
+0.9%
6M
-11.8%
YTD
+5.5%
1Y
+26.6%
2Y
+6.1%
5Y
+27.0%
10Y
+111.6%
Next earnings date
Next earnings date
04/11/2026 (in 18 days)
Volatility around earnings
~17% weaker price swings than usual
Ask the agents about Innoviva
Analyst assessment of Innoviva
PRICE TARGET LOW
US$34.00
CONSENSUS
US$38.00
MEDIAN
US$38.00
PRICE TARGET HIGH
US$42.00
0
STRONG BUY
5
BUY
4
HOLD
1
SELL
0
STRONG SELL
10
TOTAL · Buy
As of: 07/08/2026
Innoviva stock metrics
P/E
4.33
P/B
1.26
EV/EBITDA
1.63
RETURN ON EQUITY
-6.8%
NET MARGIN
-69.8%
DEBT/EQUITY
0.22
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
93.8%
FLOAT SHARES
69,201,607
AVG. DAILY VOLUME (30D)
908,473
Insider transactions (SEC)
Zhen Marianne
Basso Stephen
Raifeld Pavel
Basso Stephen
Basso Stephen
Institutional holders
Dividends & Stock splits
Dividends
Stock splits
Comparable stocks
Frequently asked questions about Innoviva stock
What does Innoviva do?
Innoviva, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Pavel Raifeld, the company employs around 159 people.
The IPO was on 05/10/2004; the stock trades on NASDAQ under the ticker INVA.
What do analysts say about Innoviva stock?
10 analysts rate the stock, the consensus is Buy (as of 07/08/2026).
The average price target is US$38.00, ranging from US$34.00 to US$42.00, with a median of US$38.00.
This is an external assessment, not a statement by Market Jury.
When does Innoviva report next?
The next earnings date is 04/11/2026.
Around past earnings, price swings were roughly -17% stronger than usual.
Does Innoviva pay a dividend?
Yes. The last dividend was US$0.25 per share, ex-date 08/09/2015, paid on 30/09/2015.
The dividend yield is 0.0% (as of 30/06/2026).
Which stocks are comparable to Innoviva?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Innoviva stock analyzed?
Clicking "Analyze stock" lets five strategies assess Innoviva against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.